Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIGN: Atrasentan in IgA Nephropathy at Risk of Progressive Renal Loss
jRCT2071210028Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Atrasentan with Placebo (2 arms). Primary endpoint: Change in proteinuria (UPCR) from Baseline to Week 36 (non-SGLT2i stratum). Started Sep 2021; status: active, not recruiting.
02
Drugs
atrasentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2071210028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210028.